Skip to main content

Table 5 Rituximab maintenance therapy for indolent lymphoma

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Study

Disease, treatment

Induction treatment

Maintenance schedule

Trial design

No. of patients

Outcomes

Study arm

Control arm

P value

Hainsworth et al. [31]

FL/SLL

R weekly (4 times)

4 weeks R q 6 months × 4 times

Randomized phase II

114

PFS (median)

31.3 months

7.4 months

0.007

Williams et al. [30]

SLL/MZL

R weekly (4 times)

R q 3 months till PD

Phase III

128

TTP (median)

4.8 years

1.4 years

0.012

Taverna et al. [37]

FL (including relapse)

R weekly (4 times)

R q 2 months for 8 month vs 5 years

Phase III

165

EFS

3.4 years (8 months)

5.3 year (5 years)

0.14

Salles et al. [28]

FL

R–CVP/R–CHOP/R-FCM

R q 2 months for 2 years

Phase III

1019

PFS (3 years)

74.9%

57.6%

< 0.0001

Rummel et al. [35]

MZL

R–B + 2R

R q 2 months for 2 years

Randomized phase II

104

PFS (median)

Not reached

92.2 months

0.008

Oh (present study)

MZL

R–CVP

R q 2 months for 2 years

Phase II

45

PFS (3 years)

81%

  1. PFS progression-free survival, EFS event-free survival, TTP time to progression, PD progression of disease, MZL marginal zone B-cell lymphoma, FL follicular lymphoma, SLL small lymphocytic lymphoma, R rituximab, MALT mucosa-associated lymphoid tissue, R–CVP rituximab-cyclophosphamide, vincristine, and prednisolone, R–CHOP rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone, R–FCM rituximab–fludarabine, cyclophosphamide, and mitoxantrone, R–Cb rituximab–chlorambucil, R–B rituximab–bendamustine